000283041 001__ 283041
000283041 005__ 20251230103618.0
000283041 0247_ $$2doi$$a10.1002/alz70857_106521
000283041 0247_ $$2ISSN$$a1552-5260
000283041 0247_ $$2ISSN$$a1552-5279
000283041 037__ $$aDZNE-2025-01448
000283041 041__ $$aEnglish
000283041 082__ $$a610
000283041 1001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b0$$eFirst author$$udzne
000283041 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283041 245__ $$aRefer‐MCI: Enriching referrals of patients to memory clinics for mild cognitive impairment (MCI)
000283041 260__ $$c2025
000283041 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767014682_31205
000283041 3367_ $$033$$2EndNote$$aConference Paper
000283041 3367_ $$2BibTeX$$aINPROCEEDINGS
000283041 3367_ $$2DRIVER$$aconferenceObject
000283041 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283041 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283041 3367_ $$2ORCID$$aOTHER
000283041 520__ $$aBackground: A timely diagnosis of mild cognitive impairment (MCI) in Alzheimer’s disease (AD) is crucial for early interventions, but its broad implementation in health-care is often challenging due to the complexity and time burden of required cognitive assessments. In the current German health care system, less than 10% of people with a clinical syndrome of MCI are being identified in primary care, even if specialists are included in the assessment. To address these challenges, the usability of new unsupervised digital remote assessment tools needs to be validated in a routine care context. Method: The Refer-MCI study will compare diagnosis and referral decisions basedon a remote digital self-assessment (neotivCare app) with usual-care based referral decision established in participating office-based specialist care. The reference test willbe the diagnosis of MCI due to AD at memory clinics according to S3 guidelines. All patients will also undergo an office-based MoCA assessment. Blood-based biomarkersfor AD (pTau-217) will be obtained at memory clinics. Result: N = 500 office-based care (N = 27 offices) patients, aged 60-80 years who seek advice for self-reported or carer-reported cognitive complaints will be screened for participation, 75% (n = 400) are expected to consent. For all patients, the office-based outpatient specialists will document their diagnosis and referral decision prior to and following the use of neotivCare. First patient in is expected in May 2025 and last patient out in February 2026. Conclusion: The goal of Refer-MCI is to investigate the potential of digital remote home-based assessment for improving efficient and timely referral of patients who are likely to have MCI from office-based specialized care to memory clinics. Refer-MCI will assess whether remote digital self-assessment of patients with memory complaints at office-based specialist care can enrich referrals to memory clinics with MCI. Refer-MCI will identify barriers for implementing tools for efficient and timely referral of these patients. Established memory clinic-based testing and blood-based biomarkers will be used as reference standard to estimate the proportion of MCI due AD among the referred patients.
000283041 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283041 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283041 650_7 $$2NLM Chemicals$$aBiomarkers
000283041 650_2 $$2MeSH$$aHumans
000283041 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000283041 650_2 $$2MeSH$$aAged
000283041 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000283041 650_2 $$2MeSH$$aAged, 80 and over
000283041 650_2 $$2MeSH$$aMiddle Aged
000283041 650_2 $$2MeSH$$aMale
000283041 650_2 $$2MeSH$$aFemale
000283041 650_2 $$2MeSH$$aReferral and Consultation
000283041 650_2 $$2MeSH$$aBiomarkers: blood
000283041 650_2 $$2MeSH$$aGermany
000283041 650_2 $$2MeSH$$aNeuropsychological Tests
000283041 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b1$$udzne
000283041 7001_ $$0P:(DE-HGF)0$$aVossfeld, Hannes$$b2
000283041 7001_ $$0P:(DE-2719)2812972$$aBerron, David$$b3$$udzne
000283041 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b4$$udzne
000283041 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b5$$udzne
000283041 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b6$$eLast author$$udzne
000283041 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70857_106521$$gVol. 21, no. S3, p. e106521$$nS3$$pe106521$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283041 8564_ $$uhttps://pub.dzne.de/record/283041/files/DZNE-2025-1448.pdf$$yOpenAccess
000283041 8564_ $$uhttps://pub.dzne.de/record/283041/files/DZNE-2025-1448.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283041 909CO $$ooai:pub.dzne.de:283041$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812972$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283041 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283041 9141_ $$y2025
000283041 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283041 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283041 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283041 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283041 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283041 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283041 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000283041 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x1
000283041 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x2
000283041 9201_ $$0I:(DE-2719)5000070$$kAG Berron$$lClinical Cognitive Neuroscience$$x3
000283041 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x4
000283041 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x5
000283041 980__ $$aabstract
000283041 980__ $$aVDB
000283041 980__ $$aUNRESTRICTED
000283041 980__ $$ajournal
000283041 980__ $$aI:(DE-2719)1510100
000283041 980__ $$aI:(DE-2719)5000006
000283041 980__ $$aI:(DE-2719)1510800
000283041 980__ $$aI:(DE-2719)5000070
000283041 980__ $$aI:(DE-2719)1011102
000283041 980__ $$aI:(DE-2719)1011103
000283041 9801_ $$aFullTexts